

MPGI STRATEGY IMPROVES AQUEOUS SOLUBILITY IF COLCHICINE SITE INHIBITORS OF TUBULIN POLYMERIZATION

M. González¹, Y. Ellahioui¹, L. Gallego-Yerga, A. Vicente-Blázquez^{1,2}, R. Álvarez¹, M. Medarde¹, R. Peláez¹.

¹ Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain, raquelalvarez@usal.es
² Laboratory of Cell Death and Cancer Therapy, Biological Research Center, CSIC, E-28040 Madrid, Spain.

INTRODUCTION AND OBJECTIVES

Antimitotic agents that bind to tubulin at colchicine site have serious drawback because of their low aqueous solubility. In this work we have design and synthesized compounds in which the classical trimethoxyphenyl moiety of colchicine site antimittotic ligands is replaced by substituted anilines.






Figure 1. Left: Schematic structure of Colchicine site in tubulin. Right: X-Ray image tubulin-colchicine complex (PDBID: 4OZB).




Scheme 1. Design of new A-ring amino derivatives.

CHEMICAL SYNTHESIS



Scheme 2. Chemical synthesis of compounds in series 1-3. Reagents, conditions, and yields: (a) HNO_3 , AcOH, 0 °C, 1-4 h, 90-94%. (b) $(\text{CH}_3)_2\text{SO}_4$, K_2CO_3 , acetone, reflux, 12-48 h, 15-88%. (c) H_2 , Pd/C, EtOAc, 48-72 h, 82-99%. (d) 4-Methoxybenzoylchloride, pyridine, CH_2Cl_2 , 4-12 h, 73-99%. (e) CH_3I , KOH, CH_3CN , 24 h, 52-98%. (f) Fomic acid, pyridine, CH_2Cl_2 , 48-72 h, 57-89%. (g) Trichloroacetic acid, NaH_2PO_4 , CH_2Cl_2 , 24-48 h, 34-95%. (h) *tert*-Butyl amine, CH_3CN , 45 °C, 24 h, 95%. (i) Acetic anhydride, pyridine, CH_2Cl_2 , 30 min-24 h, 32-90%. (j) Phosgene, CH_2Cl_2 , 30 min-24 h, 32-90%. (k) Succinic anhydride, pyridine, CH_2Cl_2 , 24 h, 29%. (l) *tert*-Butyl amine, CH_3CN , H_2O , AcOH, 0 °C, 24 h, 29%. (m) *tert*-Butyl amine, CH_3CN , reflux, 12 h, 97%. (n) Chloroacetyl chloride, CH_2Cl_2 , 12 h, 87%. (p) β -Chloroacetyl chloride, CH_2Cl_2 , 12 h, 45%. (q) Ethyl isocyanate, CH_2Cl_2 , 6 h, 73%.




Scheme 3. Chemical synthesis of compounds in series 4. Reagents, conditions, and yields: (a) $(\text{CH}_3)_2\text{SO}_4$, K_2CO_3 , acetone, reflux, 48 h, 81%. (b) $\text{HOCH}_2\text{CH}_2\text{OH}$, Toluene, Dean-Stark, 120 °C, 24 h, 96%. (c) Zn powder, AcOH, CH_2Cl_2 , 0 °C, 4-24 h, 69-98%. (d) Boc_2O , THF, reflux, 48 h, 81%. (e) HCl , H_2O , MeOH, 4 h, 97%. (f) Ac₂O, pyridine, CH_2Cl_2 , 2 h, 72%. (g) CH_3I , NaH, THF, 15 h, 75-90%. (h) *tert*-BuOH, dry THF, -78 °C to room temperature, 24 h, 47-97%. (i) POCl_3 , CH_2Cl_2 , 0 °C, 4 h, 37-83%. (j) CH_3I , acetone, reflux, 24 h, 88-97%. (k) CH_3I , AgNO_3 , acetone, 24 h, 49%. (l) TMSCl, MeOH, 24 h, 56-88%. (m) NaBH_4 , MeOH, 2 h, 95%. (n) X = Br: PBr_3 , Et₂O, 40 °C, 4 h, 98%; X = Cl: SOCl_2 , CH_2Cl_2 , (o) PPh₃, toluene, 15-24 h, 60-91%. Abbreviations: 4-MeO-Ph = 4-methoxyphenyl; 4-N(CH₃)₂-Ph = 4-dimethylaminoethylphenyl; 1-Me-5-IND = *N*-methyl-5-indolyl.


BIOLOGICAL RESULTS

Comp	Antiproliferative activity IC ₅₀ (nM) ^a			HT-29 HT-29 ^b	IC ₅₀ TPI (μM) ^c	Subst (μg/mL)
	HeLa	MCF7	HT-29			
4	>1000	>1000	>1000	n.d. ^d	>10	243
5	>1000	>1000	>1000	n.d.	>10	47
6	>1000	>1000	>1000	n.d.	>10	16
7	411	530	>1000	n.d.	>10	60
8	71	71	410	130	32.4	144
9	337	390	662	450	>10	71
10	>1000	>1000	>1000	n.d.	>10	52
11	>1000	>1000	>1000	n.d.	>10	460
12	>1000	>1000	>1000	n.d.	>10	n.d.
13	>1000	>1000	>1000	n.d.	>10	n.d.
14	>1000	>1000	>1000	n.d.	>10	n.d.
15	>1000	>1000	>1000	n.d.	>10	n.d.
16	630	n.d.	>1000	n.d.	>10	30
17a	>1000	>1000	>1000	n.d.	>10	454
17b	>1000	>1000	>1000	n.d.	>10	450
18	>1000	>1000	>1000	n.d.	>10	n.d.
19	>1000	>1000	>1000	n.d.	>10	1172
20	>1000	>1000	>1000	n.d.	>10	255
21	>1000	>1000	>1000	n.d.	>10	239
22	>1000	>1000	>1000	n.d.	>10	4409
23	227	350	187	187	>10	13
24	>1000	>1000	>1000	n.d.	>10	51
25	>1000	>1000	>1000	n.d.	>10	44
26	497	>1000	>1000	n.d.	>10	109
29	497	>1000	>1000	n.d.	>10	20
30	1670	>1000	>1000	n.d.	>10	n.d.
31	>1000	>1000	>1000	n.d.	>10	n.d.
32	>1000	>1000	>1000	n.d.	>10	n.d.
33	>1000	>1000	>1000	n.d.	>10	n.d.
34	>1000	>1000	>1000	n.d.	>10	n.d.
35	>1000	>1000	>1000	n.d.	>10	n.d.
36	>1000	>1000	>1000	n.d.	>10	n.d.
40	283	413	973	>1000	n.d.	1000
43	190	65	400	463	2.5	102
44	397	527	5000	600	5.0	110
48	190	63	636	613	6.0	n.d.
49	260	97	213	240	1.1	71
50	4570	973	>1000	n.d.	>10	1000
52	810	677	5500	927	>5	42
56	>1000	>1000	>1000	n.d.	>5	44
59	650	507	>1000	n.d.	>10	n.d.
60	13	4	309	73	0.6	52
64	400	793	>1000	n.d.	>5	62
67	13	12	303	430	1.2	10
68	>1000	>1000	>1000	n.d.	>5	63
CL-4	2	1	305	327	3	1
ABT-751	305	105	213	250	4.4	40

The amino-substituted analogs and particularly the methyl-amino ones are potent tubulin polymerization inhibitors and cytotoxic compounds against several human cancer cell lines while significantly improving the intrinsic aqueous solubility. The compounds are mostly not substrates of the MDR pump, one of the main resistance mechanisms of cancer cells in the clinic.



In agreement with tubulin inhibitory activity, the compounds cause early mitotic arrest in human cancer cell lines followed by apoptosis



Molecular modeling studies support binding at the colchicine site. Anilines located at the A ring subpocket hide the polar hydrogen on the amino groups through intramolecular hydrogen bonds to their neighboring methoxyl oxygens.

CONCLUSIONS

Hiding of polar groups in apolar environments (tubulin) while exposing them in polar solvents (water) to improve the aqueous solubility represents a new successful application of the masked polar group incorporation (MPGI) strategy towards new colchicine site antimittotic agents with improved solubility and with favorable calculated clogP and TPSA values, deemed as predictors of good absorption and low toxicity, as well.

The methylamino substituted compounds combine a nanomolar cytotoxic potency with improved water solubilities and are promising candidates for further studies.